Physiological changes related to 10 weeks of singing for lung health in patients with COPD

Mette Kaasgaard,1,2 Daniel Bech Rasmussen,2,3 Anders Løkke,3,4 Peter Vuust,1 Ole Hilberg,3,4 Uffe Bodtger2,3

ABSTRACT

Background Singing for Lung Health (SLH) was non-inferior to physical exercise training in improving 6-minute walking test distance (6MWD) and quality of life (St. George's Respiratory Questionnaire (SGRQ)) within a 10-week pulmonary rehabilitation (PR) programme for COPD in our recent randomised controlled trial (RCT) (NCT03280355). Previous studies suggest that singing improves lung function, respiratory control and dyspnoea, however this has not yet been convincingly confirmed. Therefore, this study aimed to explore the impact of SLH on physiological parameters and the associations with achieving the minimal important difference (MID) in 6MWD and/or SGRQ.

Methods We conducted post hoc, per-protocol analyses mainly of the SLH group of the RCT, exploring associations with 6MWD and SGRQ results by stratifying into achieving versus not-achieving 6MWD-MID (≥30 m) and SGRQ-MID (≤−4 points): changes in lung function, inspiratory muscle strength/control, dyspnoea, and heart rate response using logistic regression models. Further, we explored correlation and association in achieving both 6MWD-MID and SGRQ-MID (or in neither/nor) using Cohen's k and Cochran-Mantel-Haenszel Test.

Results In the SLH study group (n=108), 6MWD-MID was achieved by 31/108 (29%) and in SGRQ by 53/108 (49%). Baseline factors associated with achieving MID in either outcome included short baseline 6MWD and high body mass index. Achieving 6MWD-MID was correlated with improved heart rate response (OR: 3.14; p=0.03) and achieving SGRQ-MID was correlated with improved maximal inspiratory pressure (OR: 4.35; p=0.04). Neither outcome was correlated with significant spirometric changes. Agreement in achieving both 6MWD-MID and SGRQ-MID was surprisingly insignificant.

Conclusions This explorative post hoc study suggests that SLH has physiological impact besides being a pleasant leisure time activity in COPD. However, further studies are needed to explore associations and to conclude on benefits of SLH for COPD.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Singing for lung health (SLH) as part of community-based pulmonary rehabilitation has shown effects on walking distance and quality of life (QoL) in COPD, but current knowledge on the impact of SLH on physiological parameters is scarce.

WHAT THIS STUDY ADDS

⇒ This study suggests that improvements in 6-minute walking test and QoL during a short-term SLH programme is associated with diverse physiological changes in patients with COPD.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, AND/OR POLICY

⇒ Our findings support that SLH has physiological impact besides being a pleasant leisure time activity in COPD. However, further studies are needed to explore associations and to conclude on benefits of SLH for COPD.

INTRODUCTION

Singing has become widely acknowledged as a beneficial activity for people living with chronic respiratory disease and is proposed to improve physical, psychological, and social health.1,2 An initial body of research in respiratory disease suggests that singing addresses dyspnoea control,3–10 improves exercise capacity,11,12 enhances quality of life (QoL),3,4,13,14 and reduces anxiety and depression.13 Moreover, singing with peers builds meaningful cohesion and reduces experiences of isolation.13,14,15,16

However, it is still unclear how singing exerts its effects, that is, which specific physiological parameters may change during an effective singing training course.2–4 A recent narrative review5 suggested that singing may improve aspects in breathing pattern, respiratory control, hyperinflation, dyspnoea, health-related QoL, interoception, and physical capacity and activity in COPD. However, the authors concluded that the present evidence suffers from severe between-study heterogeneity including definitions and parameters of effectiveness. The gold standard parameter of effectiveness in pulmonary rehabilitation (PR) research is walking test...
distance, either 6-minute walking test (6MWT) or incremental shuttle walking test. In contrast, the primary outcome of the majority of studies on singing is perceived effect (qualitative or semiquantitative outcomes) and not objective parameters such as exercise capacity and physiological mechanisms. Thus, there is a lack of research on physiological changes during singing and on the association between achieving objective and subjective improvement.

We recently published results from the so-far largest randomised controlled trial (RCT) on singing compared with physical exercise training (PExT) as part of a 10 weeks’ community-based PR programme in COPD. As intervention, we used the current best-practice and disease-specific singing approach, Singing for Lung Health (SLH) and with the comparator (PExT) representing the gold standard training activity within PR. We included 270 patients with COPD and found that SLH was non-inferior to PExT in improving 6MWT distance (6MWD) (primary study outcome) and QoL (St. George’s Respiratory Questionnaire, SGRQ) (the first of several secondary study outcomes).

In the present study, we aimed to explore physiological changes related to SLH. Specifically, we aimed to investigate whether SLH was associated with physiological changes in lung function, inspiratory muscle strength and control, dyspnoea and breathing control, and exercise-induced changes in pulse and oxygen saturation. Further, we aimed to investigate associations and overlap between achieving minimal important difference (MID) in 6MWD and/or SGRQ.

To elucidate these aspects, we conducted post hoc analyses of our RCT exclusively focusing on the proportion of SLH study participants with complete data from both baseline and follow-up, thus representing the SLH per-protocol population. We hypothesised that attending SLH would be associated with positive changes in physiological parameters and mostly in persons who achieved either 6MWD-MID or SGRQ-MID. Moreover, we hypothesised that achieving 6MWD-MID and SGRQ-MID would be clearly overlapping.

**METHODS**

**Study design, oversight, participants, randomisation and blinding, and data collection**

For this post hoc, explorative study, we included data retrieved from the per-protocol RCT population (n=195), that is, patients who completed both baseline and follow-up assessments. The main focus of this paper is on inclusion criteria, procedures for randomisation, blinding, and data collection are described in our previous paper.

**Groups**

Participants were stratified accordingly:

- **Stratum 1**: Study group: SLH is the main focus of this paper, with PExT data mainly presented as supplementary data.

- **Stratum 2**: PR outcomes:
  1. Objective benefit of PR-achieving 6MWD-MID (≥30 metres) or not, and
  2. Subjective benefit of PR-achieving SGRQ-MID (≤−4.0 units) or not.

**Outcomes and measures**

Baseline characteristics included sociodemographic information, body mass index (BMI), medication usage, smoking history, expectations towards benefits of singing, forced expiratory volume in 1 s (FEV1 in L, and as percentage predicted (FEV1%)), forced vital capacity (FVC in L, and as percentage predicted (FVC%)), FEV1/FVC ratio (FEV1/FVC as percentage), forced expiratory flow (FEF25%–75% (L/s)), maximum inspiratory pressure (MIP), single breath count test, breath holding test, Modified Medical Research Council Dyspnoea Scale, modified BORG-CR10-Dyspnoea Scale, and baseline performance in 6MWD and SGRQ total score.

Effect was reported as change from baseline to follow-up concerning the following study domains and related parameters:

1. Performance in 6MWD and SGRQ, including achievement of MID (yes/no).
2. Lung function: FEV1 and FVC, both reported in litres (MID: ≥120 mL).
3. Inspiratory muscle strength and control: MIP (MID: ≥17 cm H2O; ≥10% change also explored).
4. Dyspnoea and breathing control: single breath count test (≥10% and ≥50% change).
5. Exercise-induced changes in pulse and saturation: pulse (beats/min) and heart rate response (highest pulse reached minus baseline pulse) (≥10% and ≥50% change), and Oxygen Saturation Response and Chronotropic Index (exercise-induced oxygen desaturation (EID)).

See online supplemental table S1 for details and interpretation of study outcomes and measures.

**Trial interventions**

Information on content and delivery of the 10 weeks’ trial interventions and additional patient education as part of the PR programme are reported in our previous paper and appertaining supplementary files. Content, delivery and approach of SLH have also been described previously.
Patient and public involvement

Participants were not involved in study development, recruiting or execution. We intend to enlist the support of participants in developing and implementing our dissemination strategy.

Statistics

To investigate comparability, the overall per-protocol population (n=195) was compared (SLH vs PExT). Subsequently, the SLH group (and supplementary, the PExT group) was stratified according to the two study outcomes, 6MWD and SGRQ, comparing achieved versus not achieved MID for each outcome. We used Student’s t-test in the primary analyses to test independence within continuous data (described results as mean±SD) regarding baseline, follow-up, and change values (=computed change from baseline to follow-up). Level of significance was reported as p value, and changes were presented with 95% CI. Pearson’s χ² test (or Fisher’s test) was used to test independence in distribution within categorical data (results reported as number and percentage). Within-group changes from baseline to follow-up were analysed using paired-samples tests with level of significance reported as: no star: p>0.05, *: p<0.05, **: p<0.01; ***: p<0.001.

Explanatory factors were explored in relation to the two study outcomes using logistic regression models. At first, significance was explored in all relevant variables using univariable models. Continuous variables were transposed into categories: age (transposed into tertiles), sex (male/female), BMI (transposed into tertiles), 6MWD at baseline (transposed into tertiles) and MID yes/no in FEV₁. Change in MIP was explored in categories (yes/no): ≥17 cm H₂O and ≥10% improvement. Change in single breath count test was explored in categories: ≥10% and ≥50% improvement, and changes in EID were explored in categories (yes/no): ≥10% and ≥50% improvement in heart rate and resolvement of baseline EID at follow-up.

RESULTS

Participants

The SLH study group (n=108) was retrieved from the RCT per-protocol population (n=195; representing 72% of the RCT intention-to-treat population (n=270)). 6MWD-MID was achieved by 31/108 (29%) and SGRQ-MID by 53/108 (49%) (see figure 1).

Baseline characteristics

The per-protocol populations of SLH and PExT were comparable. Overall, most were women (n=122; 62.2%), mean age was 68.9 (SD 7.9) years; mean pack years was 40.5 (SD 22.9); mean BMI was 28.2 (SD 5.9); and mean FEV₁% predicted was 51.3 (SD 15.8). Both the SLH and the PExT groups showed comparability when stratified in size (SLH: n=108; PExT: n=87). Online supplemental table S2 depicts supplementary analyses of baseline data for SLH vs PExT. Online supplemental tables S3 and S4 depict supplementary analyses of baseline characteristics in SLH and PExT, analysed in stratum 6MWD (online supplemental table S3) and stratum SGRQ (online supplemental table S4).

At baseline, SLH participants achieving 6MWD-MID had higher BMI and lower 6MWD compared with those not achieving MID (online supplemental table S3A), and those achieving SGRQ-MID had higher BMI, higher SGRQ (=lower QoL), and had lower performance in 6MWD, single breath count test, and MIP (online supplemental table S3B).

Comparing the SLH and PExT groups, we found no significant difference except that SLH participants achieving 6MWD-MID had higher BMI, lower FEV₁/FVC ratio, and lower 6MWD (online supplemental table S3A), and SLH-participants achieving SGRQ-MID had
lower BMI and lower value parameters related to lung function, inspiratory control and function, and dyspnoea control (online supplemental table S4A). In the PExT group, only educational level differed in those achieving SGRQ-MID (online supplemental table S4B).

Physiological changes in SLH
Table 1 depicts values and effects stratified by 6MWD and SGRQ in SLH (n=108) and stratified in MID achieved/not-achieved.

No significant between-group differences were observed in the 6MWD stratum (table 1). However, we observed a tendency favouring the proportion achieving SGRQ-MID and in physiological variables related to lung function, inspiratory control and function, dyspnoea and breathing control, and heart rate response, although not reaching statistical significance. Several significant within-group differences favouring the proportion achieving MID were further observed in both subgroups (SGRQ, single breath count test, and MIP).

In the SGRQ stratum (table 1), we observed that the SLH group improved significantly in 6MWD and in physiological variables related to inspiratory control and function and to dyspnoea and breathing control. We observed several within-group changes favouring the proportion achieving MID in variables related to inspiratory control and function and to dyspnoea and breathing control.

Values and effects for supplementary analyses of the PExT group are available in the supplementary files (online supplemental table S5). Briefly, in those achieving 6MWD-MID (online supplemental table S5A), we observed a tendency towards increased difference in change in QoL. Similarly, in those achieving SGRQ-MID (online supplemental table S5B), we observed a tendency towards improved EID. Compared with the SLH group, we observed fewer significant within-group differences in parameters related to inspiratory control, function, and dyspnoea or breathing control.

Relationship between SLH and physiological changes in 6MWD and SGRQ MID strata
The multivariable logistic regression analysis (table 2) included selected variables (oligo variables) based on display of significance in the initial univariable analyses, for each of the two strata: achieved 6MWD-MID (table 2) respectively SGRQ-MID (table 3).

Achieving 6MWD-MID was associated with short baseline 6MWD (OR: 6.07; 95% CI 1.4 to 0.5; p=0.01) and older age (OR: 0.13; 95% CI 0.1 to 0.6; p=0.01). We observed no baseline factors associated with achieving SGRQ-MID.

Concerning changes from baseline to follow-up in physiological parameters, achieving 6MWD-MID was associated with ≥50% improvement in heart rate response, and achieving SGRQ-MID was associated with achieving ≥10% improvement in MIP.

We found no associations in any study domain in the multivariable models PExT (online supplemental table S6).

Agreement and association between 6MWD and QoL response
Table 4 shows that achieving MID in both or neither 6MWD and SGRQ was observed in 57.4% in both the SLH and in the PExT groups, resulting in slight agreement using Cohen’s κ (SLH group: κ=0.14; p=0.14; PExT group: κ=0.11; p=0.32). In both groups, it was numerically more common to perceive an effect without improving 6MWD than to improve both.

Using the Cochrane-Mantel-Haenszel test to assess association across overall study groups (SLH and PExT), we observed a tendency towards an association. The chance-corrected proportional agreement between achieving 6MWD-MID and SGRQ-MID is depicted in online supplemental table S7.

DISCUSSION
In this post hoc explorative study, we used per-protocol data from our recent RCT12 where we compared SLH with PExT within a 10 weeks community-based PR programme. We found that SLH provided physiological improvement in patients who achieved 6MWD-MID (=physical exercise capacity) and/or SGRQ (=QoL); however, we observed more improvements in those achieving SGRQ-MID. Specifically, SLH was associated with improved MIP and single breath count test. We found no significant overlap and/or close association between achieving 6MWD-MID and/or SGRQ-MID.

Achieving 6MWD-MID and/or SGRQ-MID in SLH participants
We observed that less than a third of SLH participants (31/108) achieved 6MWD-MID, whereas almost a half (53/108) achieved SGRQ-MID (table 1). Impact of singing/SLH on exercise capacity has not yet been established, and no previous studies have reported on the proportion of participants achieving MID in walking distance tests.19-40 The improvement in SGRQ, though, falls in line with reporting of impact of singing/SLH on QoL in previous studies.3 13 14 41 42 Interestingly, the change found in this study was much larger in the 6MWD stratum and in those achieving 6MWD-MID (61.8 m (SD 41.9)) than in the intention-to-treat analysis of the RCT.12 For the SGRQ stratum, change was also higher (24.8 m (SD 43.2)) but did not reach MID. Regarding SGRQ, however, MID was achieved in both outcomes (6MWD stratum: −6.7 (SD 12.0); SGRQ stratum: −11.8 (SD 7.5)).

The SLH participants achieving 6MWD-MID had lower BMI, FEV1/FVC ratio, and 6MWD at baseline compared with those who did not achieve MID (online supplemental table S3A). Those achieving SGRQ-MID had lower BMI and lower parameters related to lung function, inspiratory control and function, and dyspnoea control (online supplemental table S4A). Evidently, it is...
### Table 1
Effect in SLH (n=108) (baseline/post/change): (1A) 6MWD-MID (≥30 m) achieved versus not achieved and (1B) SGRQ-MID total score (≤−4 units) achieved versus not achieved

|                      | Table 1A |                      | Table 1B |                      |
|----------------------|----------|----------------------|----------|----------------------|
|                      | 6MWD     | SGRQ                |          |                      |
|                      |          | Between-group       |          | Between-group        |
|                      |          | difference (P value)|          | difference (P value) |
|                      |          | 95% CI for the      |          | 95% CI for the       |
|                      |          | difference          |          | difference          |
| **Age, years**       |          |                      |          |                      |
| 68.4 (8.2)           | 0.09     | 69.6 (7.6)           | 0.12     |
| 71.4 (8.4)           |          | 71.4 (9.1)           |          |
| **Sex, female, n (%)** |          |                      |          |                      |
| 18 (58%)             | 0.83     | 31 (60.8%)           | 0.39     |
| 43 (56%)             |          | 30 (52.6%)           |          |
| **BMI**              |          |                      |          |                      |
| Baseline             |          |                      |          |                      |
| 30.9 (6.2)           | 0.003    | 29.7 (6.2)           | 0.01     |
| Follow-up            |          |                      |          |                      |
| 30.9 (6.2)           | 0.002    | 29.9 (6.2)           | 0.005    |
| Change (follow-up - baseline) | 0.29 | (−0.4 to 0.3) | 0.2 (0.9) | (−0.2 to 1.1) |
|                      |          |                      |          |                      |
| **6MWT distance**    |          |                      |          |                      |
| Baseline             |          |                      |          |                      |
| 337.2 (119.9)        | 0.01     | 363.5 (115.8)        | 0.01     |
| Follow-up            |          |                      |          |                      |
| 399.0 (108.7)        | 0.71     | 388.2 (104.6)        | 0.04     |
| Change (follow-up - baseline) | <0.001 | (−78.7 to −46.5) | 24.8 (43.2)*** | 9.9 (37.4)* |
|                      |          |                      |          |                      |
| **SGRQ total score** |          |                      |          |                      |
| Baseline             |          |                      |          |                      |
| 47.6 (17.53)         | 0.10     | 50.7 (16.1)          | <0.001   |
| Follow-up            |          |                      |          |                      |
| 40.9 (15.0)          | 0.38     | 38.9 (14.3)          | 0.19     |
| Change (follow-up - baseline) | 0.07 | (−1.2 to 8.5) | −11.8 (7.5)*** | 3.4 (5.4)*** |
|                      |          |                      |          |                      |
| **FEV₁, litres**     |          |                      |          |                      |
| Baseline             |          |                      |          |                      |
| 1.3 (0.5)            | 0.36     | 1.2 (0.5)            | 0.90     |
| Follow-up            |          |                      |          |                      |
| 1.4 (0.6)            | 0.16     | 1.3 (0.6)            | 0.89     |
| Change (follow-up - baseline) | 0.09 | (−1.5 to 0.01) | 0.0 (0.2) | (0.0 to 1.3) |
|                      |          |                      |          |                      |
| **FVC, Litres**      |          |                      |          |                      |
| Baseline             |          |                      |          |                      |
| 2.5 (0.9)            | 0.66     | 2.5 (0.7)            | 0.33     |
| 2.6 (0.9)            |          | 2.3 (0.7)            |          |
| Table 1A | Table 1B |
|----------|----------|
| **6MWD** | **SGRQ** |
| Between-group difference (P value) | 95% CI for the difference | Between-group difference (P value) | 95% CI for the difference |
| 6MWD-MID achieved (n=31) | 6MWD-MID not achieved (n=77) | | | SGRQ-MID achieved (n=53) | SGRQ-MID not achieved (n=55) |
| Follow-up | Change (follow-up - baseline) | Follow-up | Change (follow-up - baseline) | Follow-up | Change (follow-up - baseline) |
| 95% CI for the difference | | 95% CI for the difference | | 95% CI for the difference | |
| 2.6 (0.9) | 0.1 (0.5) | 2.6 (0.9) | 0.0 (0.4) | 0.90 | 90% (−0.3 to 0.1) |
| 2.5 (0.8) | 2.4 (0.7) | | | | |
| Single breath count test | | | | | |
| Baseline | 27.5 (10.2) | 26.9 (8.8) | 0.74 | 24.9 (7.5) | 29.0 (10.1) | 0.03 |
| Follow-up | 31.3 (10.1) | 28.9 (8.4) | 0.21 | 28.8 (8.5) | 30.5 (9.4) | 0.24 |
| Change (follow-up - baseline) | 3.8 (7.2)** | 1.9 (5.3)** | 0.09 | (−4.8 to 1.0) | 3.5 (5.8)** | 1.4 (5.9)** | 0.03 (−4.4 to −0.1) |
| Maximum inspiratory pressure (MIP ≥17 cm H₂O) | | | | | |
| Baseline | 55.8 (24.0) | 50.6 (19.3) | 0.24 | 48.1 (19.9) | 55.9 (23.9) | 0.03 |
| Follow-up | 62.5 (26.7) | 54.4 (19.2) | 0.08 | 55.7 (23.6) | 57.9 (20.1) | 0.21 |
| Change (follow-up - baseline) | 6.7 (12.6)** | 3.1 (10.6)** | 0.08 | (−8.8 to 1.6) | 6.9 (12.9)** | 1.47 (8.8) | 0.007 (−9.6 to −1.1) |
| ≥10% improvement, n (%) | 15 (48.0%) | 30 (40.0%) | 0.43 | 25 (52.0%) | 18 (33.0%) | 0.053 |
| Pulse | | | | | | |
| Baseline | 84.7 (13.6) | 85.1 (14.6) | 0.88 | 85.6 (15.1) | 84.4 (13.6) | 0.67 |
| Follow-up | 85.2 (13.4) | 84.9 (16.1) | 0.94 | 84.5 (13.4) | 85.5 (16.8) | 0.74 |
| Maximum heart rate during 6MWT | | | | | | |
| Baseline | 111.2 (13.1) | 117.5 (18.4) | 0.09 | 115.8 (16.2) | 115.6 (18.2) | 0.94 |
| Follow-up | 116.2 (14.2) | 115.9 (17.4) | 0.95 | 116.5 (17.1) | 0.78 |
| Heart rate response (ΔHR) | | | | | | |
| Baseline | 26.5 (13.9) | 32.4 (16.8) | 0.09 | 30.2 (18.4) | 31.1 (14.1) | 0.77 |
| Follow-up | 31.0 (13.8) | 31.0 (17.6) | 0.99 | 31.1 (16.1) | 30.9 (16.9) | 0.97 |
| Change (follow-up - baseline) | 4.5 (12.9)** | −1.2 (20.1) | 0.09 | (−12.4 to 0.9) | 0.8 (21.4) | 0.3 (15.5) | 0.89 (−7.6 to 7.1) |
| Lowest oxygen saturation during 6MWD | | | | | | |
| Baseline | 87.3 (6.5) | 88.9 (6.6) | 0.25 | 88.1 (6.2) | 87.4 (6.8) | 0.56 |
| Table 1 Continued |
|-------------------|
| **Table 1A**      |
| **Table 1B**      |
| **6MWD**          |
| **SGRQ**          |
| **Between-group** |
| difference (P    |
| value)           |
| **95% CI for the** |
| **difference**    |
| **SGRQ-MID**      |
| **achieved**      |
| **SGRQ-MID not**  |
| **achieved**      |
| **Between-**      |
| **group**         |
| **difference** (P|
| **value)**        |
| **95% CI for the** |
| **difference**    |
| **Follow-up**     |
| 68.2 (7.4)        |
| 67.7 (7.6)        |
| 0.77              |
| 88.6 (7.7)        |
| 87.2 (7.3)        |
| 0.34              |
| **Exercise-induced oxygen desaturation during 6MWT (SpO2 <88 %)** |
| **Baseline**      |
| 11 (35%)          |
| 36 (47%)          |
| 0.29              |
| 20 (39%)          |
| 27 (47%)          |
| 0.39              |
| **Follow-up**     |
| 11 (35%)          |
| 31 (44%)          |
| 0.41              |
| 18 (38%)          |
| 24 (44%)          |
| 0.53              |
| **EID (0=No EID to 1=EID only at baseline to 2=EID only at follow-up to 3=EID at baseline)** |
| **Baseline**      |
| 0                 |
| 11 (35.5%)        |
| 15 (48%)          |
| 7 (15%)           |
| 22 (47%)          |
| 23 (43%)          |
| 0.73              |
| **Follow-up**     |
| 1                 |
| 5 (16%)           |
| 9 (13%)           |
| 7 (15%)           |
| 7 (13%)           |
| 6 (11%)           |
| **Adherence to the intervention, n (%)** |
| **Baseline**      |
| 0%–49%            |
| 5 (16.1%)         |
| 12 (15.6%)        |
| 0.53              |
| 10 (19.6%)        |
| 7 (12.3%)         |
| 0.58              |
| **Follow-up**     |
| 50%–74%           |
| 7 (22.6%)         |
| 11 (14.3%)        |
| 8 (15.7%)         |
| 10 (17.5%)        |
| **75%–100%**      |
| 19 (61.3%)        |
| 54 (70.1%)        |
| 33 (64.7%)        |
| 40 (70.2%)        |
| **Smoking status, yes, n (%)** |
| **Baseline**      |
| 11 (35.5%)        |
| 15 (19.5%)        |
| 0.17              |
| 13 (25.5%)        |
| 13 (22.8%)        |
| 0.34              |
| **Follow-up**     |
| 10 (32.3%)        |
| 14 (18.2%)        |
| 0.08              |
| 12 (23.5%)        |
| 12 (21.1%)        |
| 0.91              |
| **Quit smoking during training, n (%)** |
| **Baseline**      |
| 2 (6.5%)          |
| 1 (1.3%)          |
| 0.17              |
| 13 (25.5%)        |
| 13 (22.8%)        |
| 0.34              |
| **Follow-up**     |
| 10 (32.3%)        |
| 14 (18.2%)        |
| 0.08              |
| 12 (23.5%)        |
| 12 (21.1%)        |
| 0.91              |
| **Data are presented as mean±SD unless otherwise stated. 6MWD: (MID: ≥30 m); SGRQ total score: Item (MID ≤−4 units); FEV1: (MID:≥120 mL); single breath count (MID:≥10% change); MIP (MID≥17 cm H2O. Here, ≥10% improvement is reported). EID: (SpO2<88%). Within-group significance is shown as: No star: p>0.05, *:p<0.05, **: p<0.01; ***: p<0.001. BMI, body mass index; EID, exercise-induced oxygen desaturation; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; MID, minimal important difference; MIP, maximum inspiratory pressure; 6MWD, 6-minute walking test distance; 6MWT, 6-minute walking test; SGRQ, St. George’s Respiratory Questionnaire; SLH, singing for lung health.** |
Table 2: Univariable and multivariable logistic regression in SLH: baseline factors and change factors (change from baseline to post): factors associated with achieving SLH (6MWD-MID, n=31)

| Variable | OR    | 95% CI | P value | Variable | OR    | 95% CI | P value | Variable | OR    | 95% CI | P value | Variable | OR    | 95% CI | P value |
|----------|-------|--------|---------|----------|-------|--------|---------|----------|-------|--------|---------|----------|-------|--------|---------|
| **Age**  |       |        |         | **Age**  |       |        |         | **Age**  |       |        |         | **Age**  |       |        |         |
| <65 years Base |       |        |         | >75 years Base |       |        |         | >75 years Base |       |        |         | >75 years Base |       |        |         |
| 66-75 years 0.53 | 0.2 to 0.6 | 0.21 |         | 66-75 years 0.44 | 0.1 to 1.4 | 0.16 |         | 66-75 years 0.44 | 0.1 to 1.4 | 0.16 |         | 66-75 years 0.44 | 0.1 to 1.4 | 0.16 |
| >75 years 0.17 | 0.1 to 0.6 | 0.008 |         | >75 years 0.13 | 0.03 to 0.6 | 0.01 |         | >75 years 0.13 | 0.03 to 0.6 | 0.01 |         | >75 years 0.13 | 0.03 to 0.6 | 0.01 |
| **Sex**   |       |        |         | **BMI** |       |        |         | **BMI** |       |        |         | **BMI** |       |        |         |
| Female 1.09 | 0.5 to 2.5 | 0.83 |         | Male Base |       |        |         | Male Base |       |        |         | Male Base |       |        |         |
| **BMI**   |       |        |         | **BMI** |       |        |         | **BMI** |       |        |         | **BMI** |       |        |         |
| <18.5 Empty |       |        |         | <18.5 Empty |       |        |         | 18.5-24.9 Base |       |        |         | 18.5-24.9 Base |       |        |         |
| 18.5-24.9 Base |       |        |         | 18.5-24.9 Base |       |        |         | 25-29.9 1.97 | 0.6 to 6.4 | 0.26 |         | 25-29.9 1.46 | 0.4 to 5.7 | 0.54 |         |
| 25-29.9 1.97 | 0.6 to 6.4 | 0.26 |         | 30 - 3.55 | 1.1 to 11.3 | 0.03 |         | 30 - 2.03 | 0.5 to 8.3 | 0.99 |         | 30 - 2.03 | 0.5 to 8.3 | 0.99 |
| 30 - 3.55 | 1.1 to 11.3 | 0.03 |         | 6MWD 1 5.31 | 1.7 to 16.5 | 0.004 |         | 6MWD 1 6.07 | 1.4 to 0.5 | 0.01 |         | 6MWD 1 6.07 | 1.4 to 0.5 | 0.01 |
| 6MWD 1 5.31 | 1.7 to 16.5 | 0.004 |         | 6MWD 2 1.98 | 0.58 to 6.8 | 0.28 |         | 6MWD 2 2.10 | 0.5 to 0.1 | 0.32 |         | 6MWD 2 2.10 | 0.5 to 0.1 | 0.32 |
| 6MWD 2 1.98 | 0.58 to 6.8 | 0.28 |         | 6MWD 3 Base |       |        |         | 6MWD 3 Base |       |        |         | 6MWD 3 Base |       |        |         |
| **GOLD class** |       |        |         | **GOLD class** |       |        |         | **GOLD class** |       |        |         | **GOLD class** |       |        |         |
| 1 Empty |       |        |         | 2 Base |       |        |         | 3 Base |       |        |         | 3 Base |       |        |         |
| 2 Base |       |        |         | 3 Base |       |        |         | 4 Base |       |        |         | 4 Base |       |        |         |
| 3 Base |       |        |         | 4 Base |       |        |         | 4 Base |       |        |         | 4 Base |       |        |         |
| **FEV1** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         |
| 1 0.62 | 0.2 to 1.7 | 0.36 |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| 2 0.62 | 0.2 to 1.7 | 0.36 |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| 3 0.62 | 0.2 to 1.7 | 0.36 |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| 4 0.62 | 0.2 to 1.7 | 0.36 |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| **FEV1 MID (≥120 mL)** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         | **FEV1 MID (≥120 mL)** |       |        |         |
| No Base |       |        |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| No Base |       |        |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| No Base |       |        |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| No Base |       |        |         | No Base |       |        |         | No Base |       |        |         | No Base |       |        |         |
| Variable | OR  | 95% CI | P value | Variable | OR  | 95% CI | P value | Variable | OR  | 95% CI | P value |
|----------|-----|--------|---------|----------|-----|--------|---------|----------|-----|--------|---------|
| 2        | 0.87| (0.3 to 2.4) | 0.79    | Variable |     | Yes    | 2.57    | (1.0 to 6.4) | 0.04 |
| 3        | Base|        |         |          |     |        |         | 1 (yes) | 2.04| (0.7 to 5.8) | 0.18 |
| FVC      |     |        |         | FVC     |     |        |         |          |     |        |
| 1        | 2.23| (0.7 to 7.0) | 0.17    | 1       | 1.18| (0.3 to 4.8) | 0.82    | No       | Base |     |
| 2        | 2.62| (0.9 to 7.8) | 0.09    | 2       | 1.70| (0.5 to 6.2) | 0.42    | Yes      | 1.36| (0.6 to 3.4) | 0.51 |
| 3        | Base|        |         | 3       | Base|        |         |          |     |        |
| MIP      |     |        |         | MIP MID (≥17 cm H2O) |     |        |         |          |     |        |
| 1        | Base|        |         | Yes     | 2.44| (0.8 to 7.5) | 0.12    | 1 (yes) | 1.65| (0.5 to 6.0) | 0.45 |
| 2        | 1.55| (0.2 to 1.6) | 0.26    | 2       | Base|        |         |          |     |        |
| 3        | 1.81| (0.7 to 5.0) | 0.25    | Yes     | 2.77| (0.7 to 10.4) | 0.13    | 1 (yes) | 2.16| (0.5 to 9.1) | 0.30 |
| Single breath count | |        |         | Single breath count ≥50% change | |        |         |          |     |        |
| 1        | 1.12| (0.4 to 3.0) | 0.83    | No       | Base|        |         |          |     |        |
| 2        | 1.21| (0.4 to 3.5) | 0.72    | Yes      | 1.22| (0.5 to 2.8) | 0.64    |          |     |        |
| 3        | Base|        |         |          |     |        |         |          |     |        |
| Heart rate response | |        |         | Heart rate response ≥50% change | |        |         |          |     |        |
| 1        | 3.04| (1.1 to 8.4) | 0.003   | Yes     | 2.77| (0.7 to 10.4) | 0.13    | 1 (yes) | 2.16| (0.5 to 9.1) | 0.30 |
| 2        | 0.83| (0.2 to 3.0) | 0.78    | 2       | 0.74| (0.2 to 3.1) | 0.68    | Yes      | 2.05| (0.9 to 4.8) | 0.10 |
| 3        | Base|        |         | 3       | Base|        |         |          |     |        |
| EID (SpO2≤88 %) | |        |         | EID (SpO2≤88 %) | |        |         |          |     |        |
| Yes     | 3.68| (1.4 to 9.9) | 0.01    | 1 (yes) | 3.14| (1.1 to 8.8) | 0.03    |          |     |        |

Table 2 Continued
### Table 2  Continued

#### 2A: SLH (6MWD-MID achieved: n=31)

| Variable                                      | OR     | 95% CI     | P value |
|-----------------------------------------------|--------|------------|---------|
| No Base 1 Base                               |        |            |         |
| Yes                                           | 0.63   | (0.3 to 1.5) | 0.29   |
|                                                 | 1.11   | (0.3 to 3.9) | 0.87   |
|                                                 | 1.25   | (0.4 to 4.5) | 0.73   |
|                                                 | 0.52   | (0.2 to 1.6) | 0.24   |

**Resolvement of baseline EID at follow-up**

| Variable                                      | OR     | 95% CI     | P value |
|-----------------------------------------------|--------|------------|---------|
| No Base 1 Base                               |        |            |         |
| Yes                                           | 1.45   | (0.5 to 4.7) | 0.54   |

**Adherence**

| Variable                                      | OR     | 95% CI     | P value |
|-----------------------------------------------|--------|------------|---------|
| 0%–49% Base                                   |        |            |         |
| 50%–74% Base                                  | 0.58   | (0.1 to 4.6) | 0.60   |
| 75%–100% Base                                 | 0.59   | (0.1 to 3.8) | 0.58   |

**Expectations towards benefits of singing**

| Variable                                      | OR     | 95% CI     | P value |
|-----------------------------------------------|--------|------------|---------|
| Neutral or negative                           |        |            |         |
| Positive                                      | 0.95   | (0.4 to 2.3) | 0.91   |

BMI, body mass index; EID, exercise-induced oxygen desaturation; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; MID, minimal important difference; MIIP, maximum inspiratory pressure; 6MWD, 6-minute walking test distance; SLH, singing for lung health.
Table 3  Univariable and multivariable logistic regression in SLH: baseline factors and change factors (change from baseline to post): factors associated with achieving SGRQ-MID Total Score (n=53)

| Variable | OR (95% CI) | p-value | Variable | OR (95% CI) | p-value | Variable | OR (95% CI) | p-value | Variable | OR (95% CI) | p-value | Variable | OR (95% CI) | p-value |
|----------|-------------|---------|----------|-------------|---------|----------|-------------|---------|----------|-------------|---------|----------|-------------|---------|
| Age      |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| <65 years |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| 66-75 years | 1.07 (0.4  to 2.8) | 0.90    |          | 66-75 years | 1.04 (0.4 to 3.1) | 0.94    |          | 66-75 years | 1.06 (0.4  to 3.3) | 0.92    |          |
| >75 years  | 0.44 (0.2  to 1.3) | 0.14    |          | >75 years   | 0.46 (1.1 to 1.7) | 0.25    |          | >75 years   | 0.35 (0.1  to 1.3) | 0.12    |          |
| Sex       |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| Female    | 1.37 (0.6  to 2.9) | 0.42    |          | Male        | Empty   |          | Base       | 1.30 (0.1  to 22.0) | 0.85    |          |
|           |             |         |          |            |         |          |           |         |          |             |         |          |             |         |
| BMI       |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| <18.5     |             |         |          | <18.5      | Empty   |          | 18.5-24.9  | Base      | 2.92 (2.9 to 7.9) | 0.03    |          |
| 18.5-24.9 |             |         |          | 18.5-24.9  | Base    |          | 25-29.9    | 1.17 (0.5 to 3.1) | 0.75    |          |
| 25-29.9   |             |         |          | 25-29.9    | 0.87 (0.3 to 2.5) | 0.80    |          | 25-29.9    | 0.70 (0.2  to 2.1) | 0.52    |          |
| 30-       | 2.92 (2.9 to 7.9) | 0.03    |          | 30-        | 2.42 (1.7 to 8.2) | 0.16    |          | 30-        | 1.31 (0.4  to 4.6) | 0.67    |          |
| 6MWD      |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| 1         | 3.16 (1.2 to 8.1) | 0.02    |          | 1          | 2.34 (1.7 to 7.4) | 0.15    |          | 1          | 2.61 (0.9 to 7.9) | 0.09    |          |
| 2         | 1.47 (0.6 to 3.9) | 0.43    |          | 2          | 1.33 (0.4 to 4.0) | 0.02    |          | 2          | 1.66 (0.6 to 5.1) | 0.37    |          |
| 3         | Base        |          |          | 3          | Base    |          | 3          | Base      | 1.30 (0.1  to 22.0) | 0.85    |          |
|            |             |         |          |            |         |          |           |         |          |             |         |          |             |         |
| GOLD class |             |         |          |             |         |          |             |         |          |             |         |          |             |         |
| 1         | 1.84 (0.8 to 4.2) | 0.15    |          |            |         |          |           |         |          |             |         |          |             |         |
| 2         | Base        |          |          |            |         |          |           |         |          |             |         |          |             |         |
| 3         | 1.84 (0.8 to 4.2) | 0.15    |          |            |         |          |           |         |          |             |         |          |             |         |
| 4         | 0.75 (0.2 to 2.9) | 0.67    |          |            |         |          |           |         |          |             |         |          |             |         |

Continued
Table 3 Continued

| Univariable logistic regression: Baseline factors | Multivariable logistic regression: Selected baseline factors regression model 1 | Multivariable logistic regression: Selected baseline factors regression model 2 (as FEV1 and FVC are correlated) | Multivariable logistic regression: Change factors (change from baseline to post) | Multivariable logistic regression: Selected change factors regression model 1 | Multivariable logistic regression: Selected change factors regression model 2 (as FEV1 and FVC are correlated) |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Variable | OR | 95% CI | p-value | Variable | OR | 95% CI | p-value | Variable | OR | 95% CI | p-value | Variable | OR | 95% CI | p-value | Variable | OR | 95% CI | p-value | Variable | OR | 95% CI | p-value |
| 1 | 2.71 | 1.1 to 7.0 | 0.04 | 1 | 2.99 | 0.9 to 9.6 | 0.07 | No Base | 0.0 | Base |
| 2 | 1.67 | 0.6 to 4.4 | 0.30 | 2 | 2.31 | 0.7 to 7.3 | 0.15 | Yes | 2.19 | 0.9 to 5.4 | 0.09 | Yes | 1.51 | 0.6 to 4.0 | 0.41 |
| 3 | Base | 3 | Base | FVC | FVC | FVC≥10% change | FVC 10% change | 1 | 2.65 | 1.0 to 7.1 | 0.053 | No Base | 0 | Base |
| 2 | 2.71 | 0.9 to 8.8 | 0.09 | Yes | 2.24 | 0.9 to 5.3 | 0.07 | 1 | 1.98 | 0.8 to 4.9 | 0.14 |
| 3 | Base | 3 | Base | Maximum Inspiratory Pressure (MIP) | MIP MID (≥17 cm H2O) | MIP MID (≥17 cm H2O) | MIP MID (≥17 cm H2O) | 1 | Base | No Base | 0 | Base |
| 2 | 0.86 | 0.4 to 2.1 | 0.75 | Yes | 5.10 | 1.4 to 19.3 | 0.02 | 1 | 4.35 | 1.1 to 17.6 | 0.04 | 1 | 4.58 | 1.2 to 17.6 | 0.03 |
| 3 | 0.56 | 0.2 to 1.5 | 0.24 | Single breath count | Single breath count | Single breath count | Single breath count| 1 | 2.94 | 1.2 to 7.4 | 0.02 | No Base |
| 2 | 2.56 | 0.9 to 7.0 | 0.07 | 2 | 1.63 | 0.55 to 5.2 | 0.41 | Yes | 1.35 | 0.6 to 2.9 | 0.44 | |
| 3 | Base | 3 | Base | Single breath count≥50% change | Single breath count≥50% change | Single breath count≥50% change | Single breath count≥50% change | 1 | Base | No Base |
| 2 | 1.53 | 0.6 to 3.7 | 0.35 | Yes | 1.63 | 0.4 to 6.1 | 0.47 | |
| 3 | Base | Heart rate response | Heart rate response:10% change | 1 | 0.56 | 0.2 to 1.5 | 0.26 | No Base | 0.8 to 3.9 | 0.13 | |
| 2 | 0.56 | 0.2 to 1.5 | 0.26 | Yes | 1.81 | 0.8 to 3.9 | 0.13 | |
| 3 | Base | Heart rate response:50% change | Heart rate response:50% change | 1 | 1.53 | 0.6 to 3.7 | 0.35 | No Base | 0.8 to 3.9 | 0.13 | |
| Table 3 Continued |
|-------------------|
| **Univariable logistic regression: Baseline factors** | **Multivariable logistic regression: Selected baseline factors regression model 1** | **Multivariable logistic regression: Selected baseline factors regression model 2 (as FEV<sub>1</sub> and FVC are correlated)** | **Univariable logistic regression: Change factors (change from baseline to post)** | **Multivariable logistic regression: Selected change factors regression model 1** | **Multivariable logistic regression: Selected change factors regression model 2 (as FEV<sub>1</sub> and FVC are correlated)** |
| **Variable OR 95% CI p-value Variable OR 95% CI p-value Variable OR 95% CI p-value Variable OR 95% CI p-value Variable OR 95% CI p-value Variable OR 95% CI p-value** |
| No Base | YES 1.18 (0.5 to 3.1) 0.74 |
| **EID (SpO₂ ≤ 88 %)** | **EID (SpO₂ ≤ 88 %)** | **EID (SpO₂ ≤ 88 %)** | **EID (SpO₂ ≤ 88 %)** | **EID (SpO₂ ≤ 88 %)** | **EID (SpO₂ ≤ 88 %)** |
| YES 0.73 (0.3 to 1.6) 0.42 | 1 Base |
| 2 0.96 (0.3 to 3.2) 0.94 |
| 3 1.12 (0.3 to 3.9) 0.86 |
| 4 0.68 (0.3 to 1.7) 0.41 |
| **Resolvement of baseline EID at follow-up** | **Resolvement of baseline EID at follow-up** | **Resolvement of baseline EID at follow-up** | **Resolvement of baseline EID at follow-up** | **Resolvement of baseline EID at follow-up** | **Resolvement of baseline EID at follow-up** |
| No Base | YES 1.04 (0.3 to 3.2) 0.94 |
| **Adherence** | **Adherence** | **Adherence** | **Adherence** | **Adherence** | **Adherence** |
| 0%–49% Base | 50%–74% 0.95 (0.1 to 7.2) 0.96 |
| 75%–100% 1.61 (0.3 to 10.1) 0.26 |
| **Expectations towards benefits of singing** | **Expectations towards benefits of singing** | **Expectations towards benefits of singing** | **Expectations towards benefits of singing** | **Expectations towards benefits of singing** | **Expectations towards benefits of singing** |
| Neutral or negative Base | Positive 0.95 (0.4 to 2.1) 0.90 |

Tables 2 and 3 depict univariable and multivariable logistic regression models of baseline factors and change factors, respectively, in the SLH group (identified in Table 3 and SGRQ table S). Variables for baseline were: comorbidity factors and variables for change from baseline to post were computed into defined change achieved yes/no. FEV<sub>1</sub>, MID: 120 ml. MID:≥17 cm H₂O. ORs were computed using multivariable logistic regression. OR<sub>≥1</sub> indicates an increased probability of achieving (6MWD-MID or SGRQ-MID, respectively). The multivariable logistic regression models (2A and 2B) included selected variables showing significance in the univariable analyses, leading to two different regression models. Table 3 depicts two separate multivariable models, as FEV<sub>1</sub> and FVC are correlated and should not be included in the same model.

BMI, body mass index; EID, exercise-induced oxygen desaturation; FEV<sub>1</sub>, forced expiratory volume in 1 s; MID, minimal important difference; MIP, maximum inspiratory pressure; 6MWD, 6-minute walking test distance; SGRQ, St. George’s Respiratory Questionnaire; SLH, singing for lung health.
Table 4  Association between achieving MID in both 6MWD and SGRQ (or in neither/nor) across all study groups (SLH and PExT)

| OR:1.78 p=0.065 | SGRQ-MID total score achieved |
|----------------|-------------------------------|
| SLH 6MWD-MID achieved | Yes | 19 (17.6%) | 12 (11.1%) |
| No | 33 (31.5%) | 43 (39.8%) |
| PExT Yes | 15 (17.2%) | 16 (18.4%) |
| No | 21 (24.1%) | 35 (40.2%) |

Table 4 depicts results from the Cochran-Mantel-Haenszel test for 2×2×K tables to assess association and independence between achieving 6MWD-MID and/or SGRQ-MID across both study groups (SLH and PExT).

Physiological changes in ‘effective’ SLH

A key element in singing is a controlled and coordinated breathing pattern with diaphragmatic breathing and extended expiration to support vocalisation.

The recent narrative review suggested that singing may improve aspects in breathing pattern, respiratory control, hyperinflation, dyspnoea, health-related QoL, and interoception. Improved physical capacity and activity has likewise been reported in some previous studies beyond enhanced respiratory well-being. However, specific physiological changes have not been convincingly confirmed. In accordance with formerly posed requests, the present study explored whether SLH might be associated with change in any detectable physiological parameters specifically focusing on measures reflecting lung function, inspiratory muscle strength and control, dyspnoea and breathing control, and exercise-induced changes in pulse and saturation.

Previous studies have reported that studies on singing lack consistency when addressing lung function, perceptions and clinical effects has also been addressed in previous studies and a more holistic view on effects may be relevant to consider due to the complex nature of SLH and other approaches to singing. For example, the notion of lung function may also need to include evaluation of dyspnoea, MIP and physical capacity. Previously, it has been suggested that singing improves lung function which we, however, did not observe in the present study - when measured solely by spirometry.

Interestingly, in this study, achievement of SGRQ-MID was associated with improved MIP and single breath count test (table 1) which we did not observe in the proportion of patients achieving 6MWD-MID. Furthermore, achieving SGRQ-MID was associated with a more pronounced 6MWD improvement (table 1) than the corresponding improvement in SGRQ observed in patients achieving 6MWD-MID (table 1). Surprisingly, we observed no significant associated physiological changes in PExT neither when achieving 6MWD-MID nor SGRQ-MID (online supplemental tables S5 and S6). This could suggest that SLH might provide more benefits which, however, is only speculative, not at least as the overall study groups differed in size and as it was not the aim of this study to compare SLH and PExT. We are not aware of other PR studies measuring agreement and association between objectively and subjectively defined outcomes, but several previous studies on singing have addressed a discrepancy between physiological and psychosocial benefits and, further, between perceived and clinically observed benefits.

MIP may express inspiratory muscle strength and control and may be correlated to detect changes in general muscle strength and physical capacity (6MWD). MIP has earlier been included in studies of singing and positive effects have been observed in diseases where respiratory function is also profoundly affected (for example cystic fibrosis, Parkinson’s disease), but not in COPD. This study found significant between-group changes in MIP, however, only in the SGRQ stratum.

Changes in the single breath count test might be an indication of strength, control, and coordination in the respiratory muscles, tolerance of CO₂ retention, efficiency and stability of subglottal pressure, and operating lung volumes. In our present study, single breath count test was included to indicate dyspnoea and breathing control and has previously been used in assessment of hyperventilation. Positive changes in single breath count test have been reported in some studies of singing in COPD, but not all. We observed significant improvements in both MIP and single breath count test in the SGRQ stratum (table 1) suggesting that SLH may improve inspiratory muscle strength and control and may lead to an experience of less dyspnoea and enhanced breathing control. This may be explained by the systematic training of the inspiratory and expiratory muscles during singing and the SLH programme’s focus on prolonging the expiration which may increase tolerance of hypoventilation. This training may induce lower operating volume with lower setting of tidal volume—closer to ideal resting position—and, thus, to reduction of

Table 4: Association between achieving MID in both 6MWD and SGRQ (or in neither/nor) across all study groups (SLH and PExT)
hyperinflation and perception of dyspnoea. In any case, both the MIP and the single breath count tests would be easily implementable and might be considered relevant to supplement standard assessment in COPD.53

It has been suggested that participants experience that singing/SLH provides similar effects as PExT.49 In the present study, we observed an association between achieving 6MWD-MID and improving heart rate response. This may reflect an increase in overall fitness and dynamics which may be in line with a recent study suggesting that physiological demands in SLH correspond to those of ‘brisk pace’ walking, however observed in healthy people.40

Additional tendencies (in case of exploratory acceptance of p values between 0.05 and 0.10 and/or tendencies related to within-group changes) were observed in the proportion of participants achieving 6MWD-MID regarding measures FEV1, MIP, single breath count, and heart rate response (table 1). More observations and sufficiently powered studies are needed to clarify whether the observed trends are true effects with a type II error or not.

To sum up, our study does not convincingly support that singing improves lung function as previously indicated. Rather, the study may support previous suggestions that singing/SLH may be associated with improved inspiratory muscle strength and control, dyspnoea and breathing control, and QoL. Furthermore, our study may support previous indications of SLH being associated with improved physical fitness and exercise capacity.

Strengths and limitations
The present study has both strengths and weaknesses. Previous studies on singing in respiratory disease have mainly focused on perceived effect, and studies focusing on objective parameters have largely failed to confirm these perceived benefits.1 3 4 20

Our study was based on data from a large-scale and rigorous RCT with well-described interventions and real-life delivery of community-based PR and with validated and established outcome variables commonly used in PR trials. Data were analysed and reported with transparent and basic methods,12 thus aiming to minimise selection, detection and reporting bias.

We strived for transparent analyses, reporting and discussion aiming to reduce risk of reporting and publication bias. However, the present study was obviously not powered to detect changes being an explorative study based on post hoc analyses in a selected population and, thus, with low rating in the evidence hierarchy. There are several aspects that may cause measurement and reporting bias. The small and selected population, the difference between overall study group sizes, and potential overexaggerating of findings may lead to type I error. A type II error is also possible due to different samples between the 6MWD and SGRQ strata with a smaller subgroup of participants achieving 6MWD-MID than SGRQ-MID. Furthermore, the study reflected observations from a short-term, proof-of-concept study without long-term data and without potential to address persistence of any of the observed changes. The study did not include comprehensive assessment measurements of advanced lung function measurement,50 for example static lung volumes (total lung capacity, expiratory reserve volume, residual volume), diffusion capacity for carbon monoxide, impulse oscillometry, arterial or capillary blood gas measurement, or helium dilution lung volume measurement. Neither did we include assessment of biomarkers, high-resolution chest CT, body plethysmography or ultrasound-measurement of diaphragmatic thickness or mobility to assess emphysema, hyperinflation, airway resistance, small airways involvement, or diaphragmatic strength. Neither of these are, however, standard in assessment of outcome of PR for COPD yet; however, it would be interesting and relevant to include such parameters in future research on SLH besides testing of physical activity (although challenging to measure),51 EKG, and exercise stress test, for example chair stand test, in future studies.

The study did not investigate SLH as an add-on to PExT, a combination that may likely be superior to each modality alone in providing benefits and effects and which should also be addressed in future studies. Lastly, several findings and aspects in our study remain to be sufficiently explained and are rather to be regarded as observations. Further studies are needed to investigate these aspects.

CONCLUSION
This study suggests that SLH as part of PR for COPD confers positive physiological changes besides being a pleasant leisure time activity. Future studies focusing on physiology may help us to better understand how singing works and how SLH can be used to improve the lives of patients with COPD. There is also a need to explore the apparent gap between subjective and objective benefits of SLH.

Acknowledgements The authors thank all study participants for their participation in the overall project. Additional acknowledgements related to the RCT are stated in their previous paper.

Collaborators Not applicable.

Contributors MK (study investigator), UB (principal investigator and guarantor), DBR and OH designed the scope and plan for this study. Statistical analyses and were performed by MK and DBR, and UB and OH gave feedback. MK drafted the manuscript, and UB, DBR, OH, AL and PV provided important intellectual input and feedback and approved the final version of the manuscript.

Funding This study was funded, as part of a Danish PhD project, by the Tryg Foundation, ID 111562 (DKK 967,470), the Danish Health Foundation, 18-B-0087 (DKK 200,000), Assa og Ejnar Danielsen’s Foundation, ID 10-001745 (DKK 75,000), The Moller Foundation, ID 16-204 (DKK 40,000), the Danish Lung Foundation, ID 179301-24-03-2017 (DKK 125,000), Naestved, Slagelse and Ringsted Hospitals’ Research Fund (DKK 790,190), Danish Central Region, ID 1-30-72-141-12 (100,000 DKK), Region Zealand, ID 180886, 13-000835 (DKK 314,500), and Aarhus University (DKK 793,727). Grants were used for study investigator MK’s salary, running costs and equipment. Center for Music in the Brain is funded by the Danish National Research Foundation (DNRF117).
REFERENCES

1. Kaasagaard M, Andersen IC, Rasmussen DB, et al. Heterogeneity in Danish lung choirs and their singing leaders: delivery, approach, and experiences: a survey-based study. BMJ Open 2020;10:e041700.

2. Lewis A, Philip KEJ, Lound A, et al. The physiology of singing and implications for ‘Singing for Lung Health’ as a therapy for individuals with chronic obstructive pulmonary disease. BMJ Open Respir Res 2021;8:e001260.

3. Nieminen H, Järvelä S, Anttila M, et al. Phonatory strain in singing is related to lung function and ventilatory muscle strength in patients with chronic obstructive pulmonary disease. BMJ Open 2020;10:e001206.

4. McNama RA, Epsley C, Coren E, et al. Singing for adults with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017;12:CD012296.

5. Gick ML, Nicola JJ. Singing for respiratory health: theory, evidence and challenges. Health Promot Int 2016;31:725–34.

6. Salomoni S, van den Hoorn W, Hodges P. Breathing and singing: objective characterization of breathing patterns in classical singers. PLoS One 2016;11:e0155084.

7. Leandersson R, Sundberg J, von Euler C. Role of diaphragmatic activity during singing: a study of transdiaphragmatic pressures. J Appl Physiol 1987;62:259–70.

8. Tampain J, Baker FA, Grocke D, et al. Effect of singing on respiratory function, voice, and mood after quadrupedia: a randomized controlled trial. Arch Phys Med Rehabil 2013;94:426–34.

9. Fancourt D, Finn S. What is the evidence on the role of arts in improving health and well-being? A scoping review (health evidence network [hen] synthesis report 67). Copenhagen: WHO Regional Office for Europe, 2010.

10. Heydon R, Fanctour D, Cohen AJ. The Routledge Companion to Interdisciplinary Studies in Singing. In: Wellbeing. Part I singing and health. 1st ed. Routledge, 2020. Volume III. 86–97.

11. Holland AE, Hill CJ, Jones AV, et al. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;10:CD008250.

12. Kaasagaard M, Rasmussen DB, Andreasson KH, et al. Use of singing for lung health as an alternative training modality within pulmonary rehabilitation for COPD: an RCT. Eur Respir J 2021;51:101142.

13. Bonilha AG, Onofre F, Vieira ML, et al. Effects of singing classes on pulmonary function and quality of life of COPD patients. Int J Chron Obstruct Pulmon Dis 2009;4:1–8.

14. Liu H, Song M, Zhai Z-H, et al. Group singing improves depression and life quality in patients with stable COPD: a randomized controlled trial in community-based clinic. Qual Life Res 2019;28:725–35.

15. Panigrahi A, Sohani S, Amadi C, et al. Role of music in the management of chronic obstructive pulmonary disease (COPD): a literature review. Technol Health Care 2014;22:53–61.

16. Gebauer L, Vuust P. Music Interventions in Health Care. White Paper. [Internet]. 2014; Available: http://www.petervuust.dk/wp-content/uploads/2014/03/whitepaper_digital_henselids_lidet_0.pdf

17. Stewart NAJ, Lonsdale AJ. It’s better together: The psychological benefits of singing in a choir. Psychol Music 2016;44:1240–54.

18. Pentikäinen E, Pitkäniemi A, Siponkoski S-T, et al. Beneficial effects of group singing and singing-teaching and well-being of older adults: evidence from a cross-sectional study. PLoS One 2021;16:e0245666.

19. Lord VM, Cave P, Hume VJ, et al. Singing teaching as a therapy for chronic respiratory disease—a randomised controlled trial and qualitative evaluation. BMC Pulm Med 2010;10:41.

20. Yoeli H, Macnaughton J. ‘To more than I can be’: a phenomenological meta-ethnography of singing groups for people with chronic obstructive pulmonary disease. Health 2021;25:574–95.

21. Rochester CL, Vogiatzis I, Holland AE, et al. An official American Thoracic Society/European respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med 2015;192:1373–86.

22. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;3:CD003793.

23. Lewis A, Cave P, Hodgson NS. Singing for lung health: service evaluation of the British lung Foundation programme. Perspect Public Health 2018;138:215–22.

24. Lewis A, Cave P, Hodgson NS. Singing for lung health: a qualitative assessment of a British lung Foundation programme for group leaders. BMJ Open 2020;10:e027985.

25. Holland AE, Nicol L. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:335–6.

26. Jones PW, St. George’s respiratory questionnaire: MCI. COPD 2009;6:75–9.

27. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111–24.

28. Khalil M, Wagh I, Mahmoud O. Evaluation of maximum inspiratory and expiratory pressure in patients with chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis 2014;63:329–35.

29. Sachs MC, Enright PL, Hinckley Stukovsky KD, et al. Multi-Ethnic Study of Atherosclerosis Lung Study. Performance of maximum inspiratory pressure tests and maximum inspiratory pressure reference equations for 4 race/ethnic groups. Respir Care 2009;54:1321–8.

30. Neves LF, Reis MH, Plentz RDM, et al. Expiratory and expiratory plus inspiratory muscle training improves respiratory muscle strength in subjects with COPD: systematic review. Respir Care 2012;58:1381–8.

31. McCool FD, Conomos P, Benedict JO, et al. Maximal inspiratory pressures and dimensions of the diaphragm. Am J Respir Crit Care Med 1997;155:1329–34.

32. Engin RL. The Singer’s breath: implications for treatment of persons with emphyma. J Music Ther 2005;42:29–48.

33. Kumari A, Malik S, Narkeesh K, et al. Single breath count: a simple pulmonary function test using a mobile APP. Indian J Thorac Cardiovasc Surg 2017;33:369–70.

34. MacDonald DM, Helgeson ES, Adabag S, et al. Chronotropic index and acute exacerbations of chronic obstructive pulmonary disease: a secondary analysis of block COPD. Am Ann Thorac Soc 2012;18:1795–802.

35. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495–9.

36. Lord VM, Hume VJ, Kelly JL, et al. Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial. BMC Med 2012;10:269.

37. Clift S, Skingley A, Price S. Singing for better breathing: findings from the Lambeth & Southwark singing and COPD project. Canterbury Canterbury Christ Church University, 2017.

38. Cahalan R, Green J, Meade G, et al. “SingStrong”: Singing for better lung health in COPD – A pilot study. Physiother Theory Pract 2021;37:1–9.
39 McNaughton A, Weathersall M, Williams M, et al. Sing your lungs Out-a community singing group for chronic obstructive pulmonary disease: a 1-year pilot study. BMJ Open 2017;7:e014151.
40 Philip KE, Lewis A, Buttery SC, et al. Physiological demands of singing for lung health compared with treadmill walking. BMJ Open Respir Res 2021;8:e000959.
41 Skingley A, Page S, Clift S, et al. “Singing for Breathing”: Participants’ perceptions of a group singing programme for people with COPD. Arts Health 2014;6:59–74.
42 Goldenberg RB. Singing lessons for respiratory health: a literature review. J Voice 2018;32:85–94.
43 Kerti M, Balogh Z, Kelemen K, et al. The relationship between exercise capacity and different functional markers in pulmonary rehabilitation for COPD. Int J Chron Obstruct Pulmon Dis 2018;13:717–24.
44 Skingley A, Clift S, Hurley S, et al. Community singing groups for people with chronic obstructive pulmonary disease: participant perspectives. Perspect Public Health 2018;138:66–75.
45 Oancea C. Clinical relevance of maximal inspiratory pressure: determination in COPD exacerbation. COPD, 2010: 119.
46 Irons JY, Kenny DT, McElrea M, et al. Singing therapy for young people with cystic fibrosis: a randomized controlled pilot study. Music Med 2012;4:136–45.
47 Di Benedetto P, Cavazzon M, Mondolo F, et al. Voice and choral singing treatment: a new approach for speech and voice disorders in Parkinson’s disease. Eur J Phys Rehabil Med 2009;45:13–19.
48 Stegemöller EL, Radig H, Hibbing P, et al. Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease. Disabil Rehabil 2017;39:594–600.
49 Lewis A, Thomas J. Copd and singing for lung health: a patient and clinician perspective. Pulm Ther 2018;4:121–4.
50 Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. gold executive summary. Am J Respir Crit Care Med 2017;195:557–82.
51 Rist C, Karlsson N, Necander S, et al. Physical activity end-points in trials of chronic respiratory diseases: summary of evidence. ERJ Open Res 2022;8:00541-2021–2021.